Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients

Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients

Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (α-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimmunology 2021-01, Vol.350, p.577432-577432, Article 577432
Hauptverfasser: Bilge, Nuray, Simsek, Fatma, Yevgi, Recep, Ceylan, Mustafa, Askın, Seda
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 577432
container_issue
container_start_page 577432
container_title Journal of neuroimmunology
container_volume 350
creator Bilge, Nuray
Simsek, Fatma
Yevgi, Recep
Ceylan, Mustafa
Askın, Seda
description Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (α-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, α-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, α-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral α-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum α-Syn and oligomer α-Syn levels in MS patients. The study included 60 MS patients aged 18 years or older who were admitted to the Department of Neurology between 01.02.2020–01.04.2020 and diagnosed with MS according to the 2010 MC Donald criteria, and 60 age- and sex-matched healthy controls. Those who were in the MS attack period and received cortisone treatment in the past three months were excluded from the study. The serum α-Syn and oligomer α-Syn levels of the individuals in both groups were measured. The correlation between the serum α-Syn, oligomer α-Syn, oligomer α-Syn/α-Syn ratio levels of the MS patients and their age, disease duration, number of attacks, annualized relapse rate (ARR), disease type, EDSS scores and immunomodulatory drug type used was investigated. Statistical analysis was performed using the SPSS 22.0 software. In our study, 73.3% of the MS patients were female and the mean age of the patients was 36.18 ± 9.5 years. The most common MS disease type was RRMS with 83.3%. Serum α-Syn (79.52 ± 34.81) and oligomer α-Syn (18.79 ± 10.48) levels were significantly lower in the MS patients compared to the control group (p 
doi_str_mv 10.1016/j.jneuroim.2020.577432
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2463107774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572820306937</els_id><sourcerecordid>2463107774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c283t-871b3c63328af01f306bedbf2619cc4618895cc6a619410004316568df696a3d3</originalsourceid><addsrcrecordid>eNqFkE1OwzAQhS0EoqVwhcpLNgn-SRx3B6r4qVSVBRSJlZU6E-TKSYqdFHEMLsaZcJUWiRWr0Wjem3nzITSmJKaEiqt1vK6hc42pYkYYidMsSzg7QkMqMxbJhNFjNAzCNEozJgfozPs1ITTlyeQUDThnjIg0HaKXefOBPbiuwt9f0dPrYjmd384WOK8L3Fjz1lTg_k4sbMF6bGpcdbY1GwvYawuu8cbjTd4aqFt_jk7K3Hq42NcRWt7dPk8fovnj_Wx6M480k7yNZEZXXIsQR-YloSUnYgXFqmSCTrROBJVykmot8tAnlBCS8PCSkEUpJiLnBR-hy37vxjXvHfhWVcZrsDavoem8YonglGQ7OCMkeqkOUb2DUm2cqXL3qShRO6ZqrQ5M1Y6p6pkG43h_o1tVUPzaDhCD4LoXBC6wNeCU14GChsI40K0qGvPfjR97XIqZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463107774</pqid></control><display><type>article</type><title>Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients</title><source>Elsevier ScienceDirect Journals</source><creator>Bilge, Nuray ; Simsek, Fatma ; Yevgi, Recep ; Ceylan, Mustafa ; Askın, Seda</creator><creatorcontrib>Bilge, Nuray ; Simsek, Fatma ; Yevgi, Recep ; Ceylan, Mustafa ; Askın, Seda</creatorcontrib><description>Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (α-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, α-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, α-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral α-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum α-Syn and oligomer α-Syn levels in MS patients. The study included 60 MS patients aged 18 years or older who were admitted to the Department of Neurology between 01.02.2020–01.04.2020 and diagnosed with MS according to the 2010 MC Donald criteria, and 60 age- and sex-matched healthy controls. Those who were in the MS attack period and received cortisone treatment in the past three months were excluded from the study. The serum α-Syn and oligomer α-Syn levels of the individuals in both groups were measured. The correlation between the serum α-Syn, oligomer α-Syn, oligomer α-Syn/α-Syn ratio levels of the MS patients and their age, disease duration, number of attacks, annualized relapse rate (ARR), disease type, EDSS scores and immunomodulatory drug type used was investigated. Statistical analysis was performed using the SPSS 22.0 software. In our study, 73.3% of the MS patients were female and the mean age of the patients was 36.18 ± 9.5 years. The most common MS disease type was RRMS with 83.3%. Serum α-Syn (79.52 ± 34.81) and oligomer α-Syn (18.79 ± 10.48) levels were significantly lower in the MS patients compared to the control group (p &lt; 0.001). Serum oligomer α-Syn/α-Syn ratio was higher in the MS patients compared to the control group and in SPMS compared to RRMS, but was not statistically significant. There was no significant correlation between the serum α-Syn, oligomer α-Syn and oligomer α-Syn/α-Syn ratio ratio of the MS patients and their age, disease duration, disease type, EDDS, ARR and immunomodulatory treatments. There was a significant positive correlation between α-Syn and oligomer α-Syn in MS patients (r: 0.29, p: 0.02). In our study, serum α-Syn and oligomer α-Syn levels were lower in the MS patients compared to the control group. Low levels of α-Syn in MS may play a role in the development of neuroinflammation and may be a result of the diffuse neuronal and synaptic loss. There is a need for further studies on this subject. [Display omitted] •α-Synuclein, a neuronal protein, has been associated with the inflammation and development of neurodegenerative diseases.•We report for the first time serum α-Synuclein and oligomeric α-Synuclein levels were significantly lower in MS patients.•Low serum α-synuclein values in MS patients may be associated with neuroinflammation.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2020.577432</identifier><identifier>PMID: 33220655</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><ispartof>Journal of neuroimmunology, 2021-01, Vol.350, p.577432-577432, Article 577432</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c283t-871b3c63328af01f306bedbf2619cc4618895cc6a619410004316568df696a3d3</citedby><cites>FETCH-LOGICAL-c283t-871b3c63328af01f306bedbf2619cc4618895cc6a619410004316568df696a3d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2020.577432$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33220655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bilge, Nuray</creatorcontrib><creatorcontrib>Simsek, Fatma</creatorcontrib><creatorcontrib>Yevgi, Recep</creatorcontrib><creatorcontrib>Ceylan, Mustafa</creatorcontrib><creatorcontrib>Askın, Seda</creatorcontrib><title>Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (α-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, α-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, α-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral α-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum α-Syn and oligomer α-Syn levels in MS patients. The study included 60 MS patients aged 18 years or older who were admitted to the Department of Neurology between 01.02.2020–01.04.2020 and diagnosed with MS according to the 2010 MC Donald criteria, and 60 age- and sex-matched healthy controls. Those who were in the MS attack period and received cortisone treatment in the past three months were excluded from the study. The serum α-Syn and oligomer α-Syn levels of the individuals in both groups were measured. The correlation between the serum α-Syn, oligomer α-Syn, oligomer α-Syn/α-Syn ratio levels of the MS patients and their age, disease duration, number of attacks, annualized relapse rate (ARR), disease type, EDSS scores and immunomodulatory drug type used was investigated. Statistical analysis was performed using the SPSS 22.0 software. In our study, 73.3% of the MS patients were female and the mean age of the patients was 36.18 ± 9.5 years. The most common MS disease type was RRMS with 83.3%. Serum α-Syn (79.52 ± 34.81) and oligomer α-Syn (18.79 ± 10.48) levels were significantly lower in the MS patients compared to the control group (p &lt; 0.001). Serum oligomer α-Syn/α-Syn ratio was higher in the MS patients compared to the control group and in SPMS compared to RRMS, but was not statistically significant. There was no significant correlation between the serum α-Syn, oligomer α-Syn and oligomer α-Syn/α-Syn ratio ratio of the MS patients and their age, disease duration, disease type, EDDS, ARR and immunomodulatory treatments. There was a significant positive correlation between α-Syn and oligomer α-Syn in MS patients (r: 0.29, p: 0.02). In our study, serum α-Syn and oligomer α-Syn levels were lower in the MS patients compared to the control group. Low levels of α-Syn in MS may play a role in the development of neuroinflammation and may be a result of the diffuse neuronal and synaptic loss. There is a need for further studies on this subject. [Display omitted] •α-Synuclein, a neuronal protein, has been associated with the inflammation and development of neurodegenerative diseases.•We report for the first time serum α-Synuclein and oligomeric α-Synuclein levels were significantly lower in MS patients.•Low serum α-synuclein values in MS patients may be associated with neuroinflammation.</description><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1OwzAQhS0EoqVwhcpLNgn-SRx3B6r4qVSVBRSJlZU6E-TKSYqdFHEMLsaZcJUWiRWr0Wjem3nzITSmJKaEiqt1vK6hc42pYkYYidMsSzg7QkMqMxbJhNFjNAzCNEozJgfozPs1ITTlyeQUDThnjIg0HaKXefOBPbiuwt9f0dPrYjmd384WOK8L3Fjz1lTg_k4sbMF6bGpcdbY1GwvYawuu8cbjTd4aqFt_jk7K3Hq42NcRWt7dPk8fovnj_Wx6M480k7yNZEZXXIsQR-YloSUnYgXFqmSCTrROBJVykmot8tAnlBCS8PCSkEUpJiLnBR-hy37vxjXvHfhWVcZrsDavoem8YonglGQ7OCMkeqkOUb2DUm2cqXL3qShRO6ZqrQ5M1Y6p6pkG43h_o1tVUPzaDhCD4LoXBC6wNeCU14GChsI40K0qGvPfjR97XIqZ</recordid><startdate>20210115</startdate><enddate>20210115</enddate><creator>Bilge, Nuray</creator><creator>Simsek, Fatma</creator><creator>Yevgi, Recep</creator><creator>Ceylan, Mustafa</creator><creator>Askın, Seda</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210115</creationdate><title>Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients</title><author>Bilge, Nuray ; Simsek, Fatma ; Yevgi, Recep ; Ceylan, Mustafa ; Askın, Seda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c283t-871b3c63328af01f306bedbf2619cc4618895cc6a619410004316568df696a3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilge, Nuray</creatorcontrib><creatorcontrib>Simsek, Fatma</creatorcontrib><creatorcontrib>Yevgi, Recep</creatorcontrib><creatorcontrib>Ceylan, Mustafa</creatorcontrib><creatorcontrib>Askın, Seda</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilge, Nuray</au><au>Simsek, Fatma</au><au>Yevgi, Recep</au><au>Ceylan, Mustafa</au><au>Askın, Seda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2021-01-15</date><risdate>2021</risdate><volume>350</volume><spage>577432</spage><epage>577432</epage><pages>577432-577432</pages><artnum>577432</artnum><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (α-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, α-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, α-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral α-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum α-Syn and oligomer α-Syn levels in MS patients. The study included 60 MS patients aged 18 years or older who were admitted to the Department of Neurology between 01.02.2020–01.04.2020 and diagnosed with MS according to the 2010 MC Donald criteria, and 60 age- and sex-matched healthy controls. Those who were in the MS attack period and received cortisone treatment in the past three months were excluded from the study. The serum α-Syn and oligomer α-Syn levels of the individuals in both groups were measured. The correlation between the serum α-Syn, oligomer α-Syn, oligomer α-Syn/α-Syn ratio levels of the MS patients and their age, disease duration, number of attacks, annualized relapse rate (ARR), disease type, EDSS scores and immunomodulatory drug type used was investigated. Statistical analysis was performed using the SPSS 22.0 software. In our study, 73.3% of the MS patients were female and the mean age of the patients was 36.18 ± 9.5 years. The most common MS disease type was RRMS with 83.3%. Serum α-Syn (79.52 ± 34.81) and oligomer α-Syn (18.79 ± 10.48) levels were significantly lower in the MS patients compared to the control group (p &lt; 0.001). Serum oligomer α-Syn/α-Syn ratio was higher in the MS patients compared to the control group and in SPMS compared to RRMS, but was not statistically significant. There was no significant correlation between the serum α-Syn, oligomer α-Syn and oligomer α-Syn/α-Syn ratio ratio of the MS patients and their age, disease duration, disease type, EDDS, ARR and immunomodulatory treatments. There was a significant positive correlation between α-Syn and oligomer α-Syn in MS patients (r: 0.29, p: 0.02). In our study, serum α-Syn and oligomer α-Syn levels were lower in the MS patients compared to the control group. Low levels of α-Syn in MS may play a role in the development of neuroinflammation and may be a result of the diffuse neuronal and synaptic loss. There is a need for further studies on this subject. [Display omitted] •α-Synuclein, a neuronal protein, has been associated with the inflammation and development of neurodegenerative diseases.•We report for the first time serum α-Synuclein and oligomeric α-Synuclein levels were significantly lower in MS patients.•Low serum α-synuclein values in MS patients may be associated with neuroinflammation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33220655</pmid><doi>10.1016/j.jneuroim.2020.577432</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-5728
ispartof Journal of neuroimmunology, 2021-01, Vol.350, p.577432-577432, Article 577432
issn 0165-5728
1872-8421
language eng
recordid cdi_proquest_miscellaneous_2463107774
source Elsevier ScienceDirect Journals
title Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20serum%20%CE%91-SYNUCLEIN%20and%20oligomer%20%CE%91-SYNUCLEIN%20levels%20in%20multiple%20sclerosis%20patients&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Bilge,%20Nuray&rft.date=2021-01-15&rft.volume=350&rft.spage=577432&rft.epage=577432&rft.pages=577432-577432&rft.artnum=577432&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2020.577432&rft_dat=%3Cproquest_cross%3E2463107774%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2463107774&rft_id=info:pmid/33220655&rft_els_id=S0165572820306937&rfr_iscdi=true